CNAT - Conatus Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Conatus Pharmaceuticals Inc.

16745 West Bernardo Drive
Suite 200
San Diego, CA 92127
United States
858-376-2600
http://www.conatuspharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Dr. Steven J. MentoCo-Founder, Pres, CEO & Director768.61kN/A1952
Dr. Keith W. Marshall MBA, Ph.D.Exec. VP, COO & CFO593.53kN/A1968
Dr. Alfred P. SpadaCo-Founder, Exec. VP of R&D and Chief Scientific OfficerN/AN/A1958
Mr. Alan R. EngbringExec. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

Corporate Governance

Conatus Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.